Gosset Ownership
Private
Employees
~2
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Venquis Therapeutics General Information
Developing small molecule monovalent degraders that target clinically relevant proteins in a mutant-selective fashion, degrading driver-mutant proteins while sparing corresponding wild-type proteins[1][5]
Contact Information
Website
Primary Industry
Biotech
Corporate Office
San Diego, California
United States
United States
Drug Pipeline
Pre-clinical
Key Partnerships
Venquis Therapeutics Funding
No funding data available
To view Venquis Therapeutics's complete valuation and funding history, request access »